Copper Histidinate: Pediatric First Approval

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Menkes disease is a rare genetic disorder affecting copper transport due to ATP7A gene variants.
• Impaired gastrointestinal copper absorption necessitates alternative delivery methods.
• Copper histidinate (ZYCUBO®) was developed as a bioavailable copper replacement therapy.

Purpose of the Study:

• To summarize the development milestones of copper histidinate.
• To highlight the regulatory approvals for Menkes disease treatment.

Main Methods:

• Review of development and regulatory history of copper histidinate.
• Focus on its administration as a subcutaneous injection.

Main Results:

• Copper histidinate (ZYCUBO®) received U.S. FDA approval in January 2026 for pediatric Menkes disease.
• Orphan Designation granted by the European Commission for Menkes disease treatment.

Conclusions:

• Copper histidinate represents a significant advancement in Menkes disease therapy.
• The subcutaneous administration provides a crucial treatment route for patients with absorption issues.